ASC30
Ascletis
One small molecule explored as an oral tablet and long-acting depot.
Selected study results
U.S. oral dose-finding studyPlacebo-adjusted weight-loss differencePlacebo-adjusted weight-loss difference: −7.7 percentage points · 13 weeks · Phase 2
Placebo-adjusted weight-loss difference · 13 weeks
Study focus: Weight management
Placebo-adjusted difference, not the total change in the active arm.
Adults with obesity/overweight and a weight-related complication · 60 mg once daily after titration · Trial N=125 · Sponsor topline; placebo-adjusted estimate. Results & methods ↗
Short trial. This estimate does not describe the injectable depot formulation.
Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.
Mechanism at a glance
Obesity stage by formulation
Latest: Global Phase 3 oral chronic-weight-management program initiated in August 2026; two pivotal trials are registered. Phase 2 oral and depot studies have reported results.
Next: Ascletis expects topline results from the two oral AURORA studies in the third quarter of 2028. Injectable depot development is separate.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 3 studies2 records
AURORA-1
Weight managementPivotal oral ASC30 study in adults with obesity or overweight and weight-related comorbidities; global chronic-weight-management program.
AURORA-2
Weight management with type 2 diabetesPivotal oral ASC30 study in adults with obesity or overweight and type 2 diabetes; global chronic-weight-management program.
Phase 2 studies2 records
ASC30 depot-efficacy study
Weight managementSponsor reported a 24-week U.S. Phase 2 depot-efficacy study; the linked registration began as a Phase I/IIa safety/PK study.
ASC30 tablet dose-finding study
Weight management13-week oral dose-finding study in adults with obesity or overweight and a weight-related comorbidity.
